within Pharmacolibrary.Drugs.ATC.D;

model D11AX22
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 2.383333333333333e-05,
    adminDuration  = 600,
    adminMass      = 12 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00175,
    Tlag           = 60.0,            
    Vdp             = 0.009720000000000001,
    k12             = 2.15,
    k21             = 2.15
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D11AX22</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ivermectin is a broad-spectrum antiparasitic agent used primarily for the treatment of onchocerciasis (river blindness), strongyloidiasis, and other parasitic infections. It is also approved for the treatment of scabies and certain other ectoparasitic infestations. Ivermectin has been evaluated off-label for a range of other infectious diseases but is primarily used as an antiparasitic agent. It is FDA and EMA approved for parasitic infections in humans.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers, both sexes, administered a single oral dose of ivermectin.</p><h4>References</h4><ol><li><p>Johnson-Arbor, K (2022). Ivermectin: a mini-review. <i>Clinical toxicology (Philadelphia, Pa.)</i> 60(5) 571–575. DOI:<a href=\"https://doi.org/10.1080/15563650.2022.2043338\">10.1080/15563650.2022.2043338</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35225114/\">https://pubmed.ncbi.nlm.nih.gov/35225114</a></p></li><li><p>Duthaler, U, et al., &amp; Hammann, F (2020). The effect of food on the pharmacokinetics of oral ivermectin. <i>The Journal of antimicrobial chemotherapy</i> 75(2) 438–440. DOI:<a href=\"https://doi.org/10.1093/jac/dkz466\">10.1093/jac/dkz466</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31691813/\">https://pubmed.ncbi.nlm.nih.gov/31691813</a></p></li><li><p>Sartini, I, et al., &amp; Giorgi, M (2022). Pharmacokinetics of ivermectin after oral and intravenous administration in Biłgorajska geese (. <i>New Zealand veterinary journal</i> 70(6) 313–318. DOI:<a href=\"https://doi.org/10.1080/00480169.2022.2104398\">10.1080/00480169.2022.2104398</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35852416/\">https://pubmed.ncbi.nlm.nih.gov/35852416</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D11AX22;
